All In Biotech

Free tool

FAERS Monitor: Pancreaze

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 022523 or its brand name (Pancreaze, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.

Reports

678

Serious

365

54% of reports

Hospitalization

212

Death reported

49

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea63
  • drug dose omission36
  • death29
  • abdominal pain upper28
  • infective pulmonary exacerbation of cystic fibrosis27
  • nausea27
  • pneumonia27
  • pain25
  • cystic fibrosis23
  • drug ineffective23
  • vomiting22
  • abdominal pain20
  • fatigue20
  • malaise20
  • headache19

Reports by year received

View as table
YearReports
201016
201145
201233
201312
201410
201583
201657
201753
201845
201938
202069
202145
202233
202340
202444
202529
202626

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,481 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal27154.7106.83,951
cystic fibrosisSignal23129.486.52,793
drug dose omissionSignal366.84.9172
abdominal pain upperSignal284.22.966
diarrhoeaSignal633.02.486
abdominal painSignal202.71.719
pneumoniaSignal272.61.825
vomiting221.51.03
malaise201.40.92
pain251.30.91
nausea271.10.70
death291.00.70
headache190.90.60
fatigue200.80.51
drug ineffective230.50.49

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.